Chakraborty, Debomita
Šumová, Barbora
Mallano, Tatjana
Chen, Chih-Wei
Distler, Alfiya
Bergmann, Christina
Ludolph, Ingo
Horch, Raymund E.
Gelse, Kolja
Ramming, Andreas
Distler, Oliver
Schett, Georg
Šenolt, Ladislav
Distler, Jörg H. W.
Article History
Received: 30 May 2016
Accepted: 29 August 2017
First Online: 24 October 2017
Change Date: 8 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-27450-x
Competing interests
: Although none of the authors has any direct conflict of interest related to the use or development of STAT3 inhibitors, O.D. and J.H.W.D. are involved in the development of new targeted therapies for fibrotic diseases such as SSc. O.D. has consultancy relationships and/or has received research funding from Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Roche/Genentech, Medac, Biovitrium, Boehringer Ingelheim, Novartis, 4D Science, Active Biotech, Bayer, Sinoxa, Serodapharm, EpiPharm, GSK, Pharmacyclics, and Biogen. J.H.W.D. has consultancy relationships with Actelion, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, and UCB. J.H.W.D. has received research funding from Anamar, Active Biotech, Array Biopharma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, and UCB. J.H.W.D. is stock owner of 4D Science. The remaining authors declare no competing financial interests.